uniQure/$QURE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About uniQure
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Ticker
$QURE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
209
ISIN
NL0010696654
Website
uniQure Metrics
BasicAdvanced
$815M
-
-$4.37
0.10
-
Price and volume
Market cap
$815M
Beta
0.1
52-week high
$19.18
52-week low
$4.45
Average daily volume
1.2M
Financial strength
Current ratio
11.992
Quick ratio
11.334
Long term debt to equity
1,511.483
Total debt to equity
1,522.46
Interest coverage (TTM)
-2.74%
Profitability
EBITDA (TTM)
-157.419
Gross margin (TTM)
-619.40%
Net profit margin (TTM)
-1,077.05%
Operating margin (TTM)
-851.24%
Effective tax rate (TTM)
-1.05%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-15.63%
Return on equity (TTM)
-241.16%
Valuation
Price to revenue (TTM)
36.705
Price to book
24.16
Price to tangible book (TTM)
-13.2
Price to free cash flow (TTM)
-4.429
Free cash flow yield (TTM)
-22.58%
Free cash flow per share (TTM)
-335.94%
Growth
Revenue change (TTM)
6.30%
Earnings per share change (TTM)
-29.54%
3-year revenue growth (CAGR)
-66.25%
10-year revenue growth (CAGR)
14.99%
3-year earnings per share growth (CAGR)
-14.09%
10-year earnings per share growth (CAGR)
5.63%
What the Analysts think about uniQure
Analyst ratings (Buy, Hold, Sell) for uniQure stock.
Bulls say / Bears say
uniQure's restructuring plan, announced in October 2023, is expected to result in cost savings of approximately $180 million over the next three years, extending the company's cash runway into the second quarter of 2027. (nasdaq.com)
The company reported a narrower-than-expected loss of $0.91 per share in Q3 2024, surpassing the Zacks Consensus Estimate of a loss of $1.12, indicating better financial performance than anticipated. (nasdaq.com)
In July 2024, uniQure's stock surged by 51% following positive interim clinical data from Phase I/II trials for AMT-130, showing a significant slowing in disease progression for Huntington's disease patients. (markets.businessinsider.com)
In June 2023, uniQure's stock plummeted by 40% after interim results from a Phase I/II study of AMT-130 for Huntington's disease raised concerns, including a 51.5% increase in neurofilament light chain protein levels in high-dose patients. (nasdaq.com)
In October 2024, StockNews.com downgraded uniQure's stock to a 'sell' rating, reflecting potential concerns about the company's future performance. (defenseworld.net)
In November 2024, uniQure reported Q3 revenues of $2.29 million, missing the Zacks Consensus Estimate by 16.32%, indicating potential challenges in meeting revenue expectations. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
uniQure Financial Performance
Revenues and expenses
uniQure Earnings Performance
Company profitability
uniQure News
AllArticlesVideos
uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer
GlobeNewsWire·4 weeks ago
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
GlobeNewsWire·1 month ago
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for uniQure stock?
uniQure (QURE) has a market cap of $815M as of July 11, 2025.
What is the P/E ratio for uniQure stock?
The price to earnings (P/E) ratio for uniQure (QURE) stock is 0 as of July 11, 2025.
Does uniQure stock pay dividends?
No, uniQure (QURE) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next uniQure dividend payment date?
uniQure (QURE) stock does not pay dividends to its shareholders.
What is the beta indicator for uniQure?
uniQure (QURE) has a beta rating of 0.1. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.